Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125425
Filing Date
2024-11-12
Accepted
2024-11-12 16:15:24
Documents
71
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q clsd-20240930.htm   iXBRL 10-Q 1481699
2 EX-31.1 clsd-ex31_1.htm EX-31.1 14324
3 EX-31.2 clsd-ex31_2.htm EX-31.2 14055
4 EX-32.1 clsd-ex32_1.htm EX-32.1 9293
5 GRAPHIC img142404377_0.jpg GRAPHIC 102354
6 GRAPHIC img142404377_1.jpg GRAPHIC 54604
  Complete submission text file 0000950170-24-125425.txt   7141857

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20240930.xsd EX-101.SCH 1162373
73 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20240930_htm.xml XML 1039481
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

IRS No.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37783 | Film No.: 241448372
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)